Results 21 to 30 of about 1,627,756 (267)

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

Liver Cancer, 2021
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH ...
M. Kudo, Y. Kawamura, K. Hasegawa, R. Tateishi, K. Kariyama, S. Shiina, H. Toyoda, Y. Imai, A. Hiraoka, M. Ikeda, N. Izumi, M. Moriguchi, S. Ogasawara, Y. Minami, K. Ueshima, T. Murakami, S. Miyayama, O. Nakashima, H. Yano, M. Sakamoto, E. Hatano, M. Shimada, N. Kokudo, S. Mochida, T. Takehara   +24 more
semanticscholar   +1 more source

Management of hepatocellular carcinoma: An update

Hepatology, 2011
Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
J. Bruix, M. Sherman
semanticscholar   +1 more source

MLN2238 exerts its anti-tumor effects via regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma

Frontiers in Pharmacology, 2022
Background: Intrahepatic Cholangiocarcinoma (iCCA) is a highly malignant tumor with limited treatment options that contributes largely to cancer-related deaths worldwide.
Hao Xu, Hao Xu, Hao Xu, Hao Xu, Hao Xu, Hao Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Guangyu Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Qianhui Xu, Chang Xu, Chang Xu, Chang Xu, Chang Xu, Chang Xu, Chang Xu, Xiaohu Zhou, Yang Bai, Yang Bai, Yang Bai, Yang Bai, Yang Bai, Yang Bai, Lu Yin, Yuan Ding, Yuan Ding, Yuan Ding, Yuan Ding, Yuan Ding, Yuan Ding, Weilin Wang, Weilin Wang, Weilin Wang, Weilin Wang, Weilin Wang, Weilin Wang   +43 more
doaj   +1 more source

Epidemiology of Hepatocellular Carcinoma

Hepatology, 2020
Liver cancer is a major contributor to the worldwide cancer burden. Incidence rates of this disease have increased in many countries in recent decades.
K. McGlynn, J. Petrick, H. El‐Serag
semanticscholar   +1 more source

Elevated N‐methyltransferase expression induced by hepatic stellate cells contributes to the metastasis of hepatocellular carcinoma via regulation of the CD44v3 isoform

Molecular Oncology, 2019
The cross‐talk between hepatic stellate cells (HSCs) and hepatic carcinoma cells contributes to hepatocellular carcinoma (HCC) progression, but the underlying mechanism is largely unknown.
Jie Li, Song You, Sheng Zhang, Qing Hu, Fuqiang Wang, Xiaoqin Chi, Wenxiu Zhao, Chengrong Xie, Changmao Zhang, Yaqi Yu, Jianmin Liu, Yue Zhao, Pingguo Liu, Yi Zhang, Xujin Wei, Qiu Li, Xiaomin Wang, Zhenyu Yin   +17 more
doaj   +1 more source

hsa_circ_0006916 promotes hepatocellular carcinoma progression by activating the miR-337-3p/STAT3 axis

Cellular & Molecular Biology Letters, 2020
Background Circular RNAs (circRNAs) are thought to be involved in the development of various malignancies. The expression and function of hsa_circ_0006916, a newly identified circRNA, in hepatocellular carcinoma remain unclear.
Xiao-Yong Zhou, Hui Yang, Yang-Qiu Bai, Xiu-Ling Li, Shuang-Yin Han, Bing-Xi Zhou   +5 more
doaj   +1 more source

Basic and Clinical Research Progress of Immunotherapy for Hepatocellular Carcinoma

Zhongliu Fangzhi Yanjiu, 2023
Primary liver cancer, especially hepatocellular carcinoma, poses a serious threat to the life and health of the Chinese people. Given the insidious onset of liver cancer, less than 30% of hepatocellular carcinoma patients are considered for radical ...
ZHANG Zechuan, SUN Beicheng
doaj   +1 more source

CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis

Journal of Experimental & Clinical Cancer Research, 2019
Background CDK5, an atypical member of the CDK family, play a significant role in the tumorigenesis of multiple organ, but CDK5 and its substrates in genesis and development of HCC is still unclear.
Fuqiang Wang, Wenxing Zhao, Yuehong Gao, Jiechao Zhou, Huifang Li, Guanyun Zhang, Dong Guo, Chengrong Xie, Jie Li, Zhenyu Yin, Jie Zhang   +10 more
doaj   +1 more source

Spatially resolved visualization of reprogrammed metabolism in hepatocellular carcinoma by mass spectrometry imaging

Cancer Cell International, 2023
Background Metabolic reprogramming refers to tumor-associated metabolic alterations during tumorigenesis and has been regarded as one of the most important features of cancer.
Bangzhen Ma, Yang Zhang, Jiwei Ma, Xinguo Chen, Chenglong Sun, Chengkun Qin   +5 more
doaj   +1 more source

Advances in immunotherapy for hepatocellular carcinoma

Nature reviews: Gastroenterology & hepatology, 2021
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs ...
B. Sangro, P. Sarobe, S. Hervás-Stubbs, I. Melero   +3 more
semanticscholar   +1 more source